Form 4: Vivani Medical Director Aaron Mendelsohn Granted Stock Options

Aaron Mendelsohn, a director at Vivani Medical, Inc., was granted stock options on June 27, 2024, according to a recent SEC filing.

Summary

• Aaron Mendelsohn, a director of Vivani Medical, Inc., was granted 34,839 stock options on June 27, 2024.
• The options have an exercise price of $1.27 and expire on June 26, 2034.
• The options vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, contingent upon continued service.
• A Limited Power of Attorney was executed on December 6, 2023, appointing Adam Mendelsohn, Judy Wong, and Brigid Makes as attorneys-in-fact to handle SEC filings on behalf of Aaron Mendelsohn.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns the interests of the director with those of the shareholders. There are no indications of negative news or concerns.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation packages.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term commitment and value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director benefits from the potential future value of the stock options.

Key Dates